Global Type 2 Diabetes Drug Market (T2D) Forecast & Analysis to 2022 in a New Research Report at MarketOptimizer.org

MarketOptimizer.org offers “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, Texas (PRWEB) March 24, 2014

This report focuses on type 2 diabetes pharmaceuticals in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) and three emerging markets (China, India and Brazil). These 10 markets will be referred to as the global market. The global type 2 diabetes pharmaceutical markets in the 2012 base year were $28.1 billion, including both branded and generic drugs. Branded products alone accounted for $19.2 billion across the 10 markets. At 58% of the overall type 2 diabetes market, the US is clearly the dominant market, totaling $16.4 billion in branded and generic pharmaceutical sales. This is due to the much higher prices of pharmaceuticals in this country and due to the high diagnosed prevalence. The next-largest individual market is Japan, at 9% of the worldwide type 2 diabetes market, totaling $2.5 billion. The 5EU countries make up 18%, while emerging markets, including India, China and Brazil together, account for 15% of the total market.

Complete report is available at http://www.marketoptimizer.org/pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2022-event-driven-update.html.

Over the forecast period, emerging markets will grow in size most rapidly, due to a dramatic increase in the prevalence and diagnosis of type 2 diabetes, which are attributed to increased life expectancy and lifestyle changes that have occurred through rapid economic growth. Uptake of branded drugs will also increase in these markets due to fast growth of the middle class. Sales in the US will grow by about 9% per year over the forecast period. The European and Japanese markets will also increase steadily; however, cost constraints in Europe and the slow regulatory process in Japan will slightly limit growth in these regions.

Corporate Shift in Focus from Therapeutic Value towards Competitive Pricing

Historic leaders in the type 2 diabetes spaces include Novo Nordisk, Bristol-Myers Squibb, Sanofi, Novartis, GlaxoSmithKline, Merck, Eli Lilly and Takeda; AstraZeneca and Boehringer Ingelheim have recently entered the space through the formation of partnerships. All of these companies have had or will have blockbuster drugs in this space. Takeda and GlaxoSmithKline faced a large patent cliff in 2012 with the loss of market exclusivity for their blockbuster drugs, Actos and Avandia, respectively. Avandia’s patient share dropped sharply even before the patent cliff due to its adverse effects. Takeda is compensating for Actos’ loss of patent protection by strengthening its diabetes portfolio through partnerships, but also by developing some novel, first-in-class molecules. Novo Nordisk, Sanofi and Eli Lilly are all facing patent expiry for their blockbuster insulin analogs (Novolog, Lantus and Humalog, respectively) this and next yearin 2013 and 2014, and will suffer erosion to biosimilars from around 2015, when presumably all the regulations for biosimilar insulin production will be in place. The companies are undertaking different strategies, whereby they either go on the offense or defense, to address this problem. Eli Lilly already has a Lantus biosimilar in late-stage development, which will be a strong competitor to Sanofi’s Lantus, while Sanofi is developing a superior version of its own product Lantus and also a fixed-dose combination of Lantus and Lyxumia in order to protect its own franchise. Sanofi is also stepping up its biosimilar insulin development program and expects to have two projects in clinical development soon, which are likely to be versions of Eli Lilly's Humalog and Novo Nordisk's Novolog. Only Novo Nordisk does not have a biosimilar insulin strategy, which reflects its existing portfolio of novel insulin analogs in development.

Future leaders during the forecast period will include Novo Nordisk, AstraZeneca, Merck, Eli Lilly/Boehringer Ingelheim, Takeda, and Johnson & Johnson. All of these companies have late-stage pipeline products or very recently marketed products that have the potential to strengthen significantly the companies’.

Reasons to buy

  • Develop and design you’re in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Purchase a copy of this report at http://www.marketoptimizer.org/contacts/purchase?rname=5901.

Explore more market research reports on Pharmaceuticals at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals.

About Us:
MarketOptimizer.org (http://www.marketoptimizer.org/) is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.


Contact

Follow us on: Contact's Google Plus